Hanmi Pharmaceutical
128940.KS · Bio
Korea's largest pharmaceutical company by revenue. Known for proprietary LAPSCOVERY long-acting platform technology, with multi-billion-dollar global licensing deals in obesity and diabetes therapeutics.
Latest news
Hanmi Science Faces Margin-Call Risk as Top Shareholder Is Reported to Police
Hanmi Creates Mascot 'Anne' to Unify OTC Brand Marketing
Hanmi Pharmaceutical Target Price Raised 12% on Roche Obesity Push
Hanmi Pharmaceutical Target Price Raised 12% After Roche Licensing Deal
Hanmi Pharmaceutical Trains AI on 4,000 Quality Documents
Hanmi Pharmaceutical Completes Phase 2 Dosing of Rare Disease Drug
MSD Sees Korean Innovation Driving Next Wave of Keytruda Advances
Hanmi Science Ties Up With Megazone on AI Transformation
Hanmi Resumes Venture Investing to Widen Open Innovation
Hanmi Pharmaceutical Lands $3.5 Billion in Licensing Deals in Three Months
Pancreatic Cancer Targeted Therapy Wins First FDA Approval
Hanmi Obesity Pipeline Gains Value After $2.3 Billion Genentech Deal
Hanmi Rerated on $2.4 Billion Genentech Deal, More Licensing Seen
Top Traders Buy Samsung, SK hynix on Chip Dip, Sell Hanmi Pharm
D&D Pharmatech to Unveil Muscle-Sparing Obesity Drug Data at U.S. Meeting
Genentech Expands Personalized Obesity Strategy With Hanmi's Muscle-Sparing Drug
Preserving Muscle While Cutting Fat: A Game Changer in the $97 Billion Obesity Market
Hanmi Licenses Obesity Drug to Genentech in $2 Billion Deal
Hankook's Lim Ju-hyun Bets on R&D, Lands $2.3 Billion Drug Deal
Korean Firms Disclose Major Contracts and Deals on the 24th
Hanmi Pharm Hits Ceiling on $2.3 Billion Obesity Drug Licensing Deal
Hanmi Licenses Muscle-Sparing Obesity Drug to Genentech in $2 Billion Deal